Enhertu Recommended for EU Approval in HER2-Positive Metastatic Solid Tumours
AZN sits 44% above its 52-week low of $131.03.
Summary
AstraZeneca's Enhertu has received a positive recommendation from the CHMP for EU approval in HER2-positive metastatic solid tumours, marking a potential first-in-class, tumour-agnostic indication.
Key Events · Product Development and Regulatory · AZN
-
EU Regulatory Recommendation
The Committee for Medicinal Products for Human Use (CHMP) has recommended Enhertu for approval in the EU as a monotherapy for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior treatment and have no satisfactory treatment options.
-
Broad Tumour Agnostic Indication
This recommendation is for a 'tumour agnostic' indication, meaning it applies across a broad range of HER2-positive solid tumours, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, non-small cell lung, and colorectal cancers.
-
Potential First-in-Class Therapy
If approved, Enhertu would become the first HER2-directed therapy and antibody drug conjugate to receive a tumour agnostic indication in the EU, addressing a significant unmet medical need.
-
Based on Positive Phase II Trials
The positive opinion is based on clinically meaningful responses observed in a subgroup of patients with HER2-positive (IHC 3+) tumours across three Phase II trials: DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02.
Analysis · AZN · Life Sciences
The CHMP's positive opinion for Enhertu represents a significant regulatory milestone, potentially opening up a broad new market in the EU for AstraZeneca and Daiichi Sankyo. The 'tumour agnostic' indication means Enhertu could be used across various HER2-positive solid tumours, addressing an unmet need where targeted treatment options are currently limited. This expands the drug's commercial potential beyond specific cancer types and reinforces its position as a leading oncology asset.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 51.2% of the 201 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $188.70 on NYSE in the Life Sciences sector, with a market capitalization of approximately $290.1B. The 52-week trading range was $131.03 to $212.71. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.